Amylin Chair And Lead Independent Director Voted Off The Board
This article was originally published in The Pink Sheet Daily
Executive Summary
The ouster underscores the extent to which dissident shareholders, led by Carl Icahn, have had influence as Amylin hopes to win approval of a key diabetes drug.
You may also be interested in...
Byetta Needs More Studies To Determine Pancreatitis Risks, FDA Says
The previously undisclosed requirements are a setback to Amylin and Lilly, which jointly market the drug and plan a once-weekly version.
Byetta Needs More Studies To Determine Pancreatitis Risks, FDA Says
The previously undisclosed requirements are a setback to Amylin and Lilly, which jointly market the drug and plan a once-weekly version.
But Who’s Counting? Icahn Wins A Biogen Seat, Another Is “Too Close To Call”
After a drama-packed shareholder meeting on June 3, Carl Icahn claims he won two of four contested seats on the 13-person, Biogen Idec board